Repligen Corp

RGEN

Equity

ISIN US7599161095 / Valor 965900

NASDAQ (2024-09-16)

USD 140.00+0.01%

Repligen Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Repligen Corp is a company that provides technology solutions for the development and manufacture of various biopharmaceutical products, including plasmid DNA, viral vectors, mRNA, and new modalities like whole cells and cultivated meat. With over 15 years of experience and a track record of successful implementation in commercial processes, Repligen's XCell® ATF Technology stands out as a scalable and efficient method for upstream intensification. Additionally, the company offers the CTech™ FlowVPX® spectrophotometer system, designed to meet regulatory GMP requirements by providing reliable real-time concentration measurements throughout the downstream process.

Summarized from source with an LLMView SourceSector: Technology

Revenue Performance

Repligen Corp reported second quarter revenue of $154 million for Q2 2024, slightly down from $159 million in Q2 2023. Despite this, the company achieved its first half revenue target with a total of $305 million, indicating a strong performance in the first half of the year.

Order Highlights

In Q2 2024, Repligen Corp received orders totaling $157 million, resulting in a book-to-bill ratio of 1.02 for the quarter and 1.01 year-to-date. This reflects continued strong demand, particularly from the Pharma sector and a resurgence in CDMO activity.

Profit Margins

Repligen Corp's GAAP gross profit for Q2 2024 was $77 million, compared to $80 million in Q2 2023. Adjusted gross profit was $76 million, down from $80 million. The GAAP operating margin was 1.0%, a significant decrease from 12.2% in the previous year, while the adjusted operating margin was 10.1%, down from 18.5%.

Net Income

For Q2 2024, Repligen Corp reported a GAAP net income of $3 million, a decrease from $20 million in Q2 2023. Adjusted net income was $19 million, down from $30 million in the same quarter last year. GAAP earnings per share were $0.06, compared to $0.35, while adjusted earnings per share were $0.33, down from $0.53.

Financial Guidance

Repligen Corp has narrowed its revenue guidance for the full fiscal year 2024 to a range of $620 million to $635 million, reflecting a slight adjustment due to incremental weakness in China. The adjusted EPS guidance remains unchanged, indicating confidence in achieving the projected earnings despite the revenue adjustment.

Summarized from source with an LLMView Source

Key figures

-15.4%1Y

-53.3%3Y

76.1%5Y

Performance

45.1%1Y

50.6%3Y

48.5%5Y

Volatility